Clinical Startup of the 670G Closed Loop Insulin Delivery System

Completed

Conditions studied: Diabetes Mellitus, Type 1

In brief

The purpose of this project is to track initiation and the first year of clinical use of the newly FDA approved 670G closed loop insulin delivery system by patients who have requested this system. Our goal is to evaluate our clinical approach to starting this newly approved system. Since the investigators are only following patients who have already decided to start the 670G, the investigator does not assign specific interventions to the subjects of the study; thus this is a Observational study.

Key facts

Study ID

NCT03017482

Run by

Stanford University

People needed

85

Starts

2017-07-15

Expected to finish

2019-08-30

Last updated by the study team

2019-09-19

Who can join

Age: 7 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of type 1 diabetes The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.
• Clinically planning to and be able to start the Medtronic 670G closed loop system
• Age greater than 7.00 years at the initiation of the 670G system
• Total daily insulin use of great than 8.0 units per day over a 1 week period
• Willing and able (access to internet from home) to download information into the Medtronic CareLink software

You may not qualify if…

• 1) Current or planned pregnancy (for the next 12 months)

Where it is running

• Stanford University — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.